STRO vs VTR
Sutro Biopharma (STRO) versus Ventas Inc (VTR) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Ventas Inc (VTR) is a reit - healthcare facilities company listed on NYSE.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported VTR revenue for 2024-12-31 was $4.92B. Net income was $88.4M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
STRO currently screens at market cap $470.8M. VTR currently screens at market cap $39.94B and trailing P/E 149.4.
Not investment advice. Open the STRO and VTR stock pages for the full models.
Not investment advice.